The earnings call highlighted significant advancements in Vistagen's clinical programs and financial stability, despite increased R&D expenses and net loss. The company's progress in clinical trials and pipeline expansion is promising, although there are operational challenges such as the termination of a trial site.

Company Guidance

During Vistagen Therapeutics' Fiscal Year 2026 First Quarter Corporate Update Conference Call, guidance was provided on the progress of their late-stage clinical programs. The company is advancing its intranasal pherine programs, focusing on nose-to-brain neurocircuitry to address disorders with suboptimal care standards. Their lead product, intranasal fasedienol, is in late Phase III development for treating social anxiety disorder (SAD), affecting over 30 million adults in the U.S. The company anticipates top-line data from the PALISADE-3 Phase III trial in Q4 2025 and similar results from PALISADE-4 in the first half of 2026. These trials use a public speaking challenge design and aim to support a potential new drug application submission to the FDA. Additionally, Vistagen is planning further Phase II development for Itruvone and PH80, targeting major depressive disorder and menopausal hot flashes, respectively, with a U.S. IND submission for PH80 expected in Q4 2025. Financially, research and development expenses rose to $11.7 million from $7.6 million year-over-year, with a net loss of $15.1 million compared to $10.7 million the prior year. As of June 30, 2025, the company held $63.2 million in cash and equivalents.

Advancement of Clinical Programs

Vistagen has made significant progress in its late-stage clinical programs, particularly with its lead product candidate, intranasal fasedienol, which is in Phase III trials for the treatment of social anxiety disorder (SAD). The company expects top-line data from the PALISADE-3 trial in Q4 2025 and PALISADE-4 in the first half of 2026.

Expansion of Product Pipeline

Vistagen is advancing additional product candidates, including Itruvone for major depressive disorder and PH80 for menopausal hot flashes, with plans to submit a U.S. IND for PH80 in Q4 2025.

Strong Financial Position

The company reported $63.2 million in cash, cash equivalents, and marketable securities as of June 30, 2025, providing a stable financial footing to support ongoing research and development efforts.

High Conversion and Retention Rates

In the trials, Vistagen is seeing encouraging conversion rates of over 80% from the randomized study into the open label extension, with good retention rates as well.

VistaGen Therapeutics (VTGN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

VTGN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2026 (Q2)	-0.48 / -	-0.42	―	―	―
Aug 07, 2025	2026 (Q1)	-0.47 / -0.47	-0.35	-34.29% (-0.12)	―
Jun 17, 2025	2025 (Q4)	-0.50 / -0.43	0.3	-243.33% (-0.73)	―
Feb 13, 2025	2025 (Q3)	-0.51 / -0.46	-0.22	-109.09% (-0.24)	―
Nov 07, 2024	2025 (Q2)	-0.39 / -0.42	-0.66	36.36% (+0.24)	―
Aug 13, 2024	2025 (Q1)	-0.40 / -0.35	-0.94	62.77% (+0.59)	―
Jun 11, 2024	2024 (Q4)	-0.36 / 0.30	-1.61	118.63% (+1.91)	―
Feb 13, 2024	2024 (Q3)	-0.30 / -0.22	-1.5	85.33% (+1.28)	―
Nov 09, 2023	2024 (Q2)	-0.68 / -0.66	-2.4	72.50% (+1.74)	―
Aug 10, 2023	2024 (Q1)	-0.86 / -0.94	-3	68.67% (+2.06)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

VTGN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$2.73	$2.97	+8.79%
Jun 17, 2025	$2.38	$2.06	-13.45%
Feb 13, 2025	$2.85	$2.97	+4.21%
Nov 07, 2024	$3.12	$3.14	+0.64%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does VistaGen Therapeutics (VTGN) report earnings?

VistaGen Therapeutics (VTGN) is schdueled to report earning on Nov 06, 2025, TBA (Confirmed).

What is VistaGen Therapeutics (VTGN) earnings time?

VistaGen Therapeutics (VTGN) earnings time is at Nov 06, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is VTGN EPS forecast?

VTGN EPS forecast for the fiscal quarter 2026 (Q2) is -0.48.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing